Drug Profile
Rhinovirus vaccine - Meissa Vaccines
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Meissa Vaccines
- Developer Emory University; Meissa Vaccines
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Rhinovirus infections (Prevention) in USA (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rhinovirus-infections(Prevention) in USA (Parenteral)
- 10 May 2017 Meissa Vaccine receives phase I SBIR grant from National Institutes of Health for rhinovirus vaccine development in Rhinovirus infections